castration-resistant prostate cancer
GPTKB entity
Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:associated_with |
poor prognosis
increased levels of testosterone |
| gptkbp:can_lead_to |
metastatic disease
pain management issues |
| gptkbp:has_achievements |
skeletal-related events
|
| gptkbp:hosts |
gptkb:vaccine
|
| https://www.w3.org/2000/01/rdf-schema#label |
castration-resistant prostate cancer
|
| gptkbp:involves |
genetic mutations
|
| gptkbp:is_a |
malignant neoplasm
|
| gptkbp:is_affected_by |
genetic predisposition
|
| gptkbp:is_associated_with |
increased healthcare costs
increased risk of fractures tumor microenvironment changes neuroendocrine differentiation increased risk of cardiovascular events increased pain levels |
| gptkbp:is_characterized_by |
tumor heterogeneity
progressive disease hormonal resistance resistance to androgen deprivation therapy |
| gptkbp:is_considered |
chronic condition
advanced stage of prostate cancer therapeutic challenge |
| gptkbp:is_evaluated_by |
clinical assessments
biopsy radiological assessment serum biomarkers |
| gptkbp:is_influenced_by |
lifestyle factors
|
| gptkbp:is_linked_to |
increased mortality
increased anxiety levels increased androgen receptor activity increased fatigue increased incidence of depression |
| gptkbp:is_often_associated_with |
psychosocial challenges
|
| gptkbp:is_often_used_in |
older men
|
| gptkbp:is_part_of |
oncology research
urological oncology prostate cancer continuum |
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:is_subject_to |
gptkb:municipality
ongoing research |
| gptkbp:is_used_for |
weight loss
bone pain urinary symptoms heterogeneous behavior |
| gptkbp:managed_by |
palliative care
oncologists pain relief strategies |
| gptkbp:occurs_in |
initial hormone therapy
|
| gptkbp:recognizes |
imaging studies
|
| gptkbp:requires |
nutritional support
supportive care radiation therapy multidisciplinary approach hormonal manipulation |
| gptkbp:research_focus |
novel therapeutic agents
|
| gptkbp:social_responsibility |
PSA testing
|
| gptkbp:treatment |
gptkb:docetaxel
gptkb:abiraterone chemotherapy hormonal therapy radium-223 cabazitaxel enzalutamide sipuleucel-T |
| gptkbp:bfsParent |
gptkb:ALX-0688
|
| gptkbp:bfsLayer |
5
|